Erste Group upgraded Amgen (AMGN) to Buy from Hold. The firm says Amgen has a higher operating margin and return on equity than the sector average. In addition, the company’s MariTide is the first obesity treatment with monthly or less frequent dosing to demonstrate safe weight loss in a Phase 2 study, the analyst tells investors in a research note. Erste sees a “favorable” valuation at current share levels.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMGN: